Supplemental Online Content

Mao JJ, Liou KT, Baser RE, et al. Effectiveness of electroacupuncture or auricular acupuncture vs usual care for chronic musculoskeletal pain among cancer survivors: the PEACE randomized clinical trial. *JAMA Oncol.* Published online March 18, 2021. doi:10.1001/jamaoncol.2021.0310

eAppendix. Acupuncture Intervention

eTable 1. Descriptive Statistics of Pain Outcome Measures, by Week and Arm

eTable 2. Primary and Secondary Outcomes (extended version of manuscript Table 2)

This supplemental material has been provided by the authors to give readers additional information about their work.

Memorial Sloan Kettering Cancer Center IRB Number: 16-1579 A(14) Approval date: 21-Jan-2020

Appendix: Acupuncture Intervention

Description of the Intervention:

i. <u>Electro-Acupuncture (EA) procedure</u>: The following acupuncture treatment was developed by Dr. Mao and based on classic acupuncture text books in both Chinese and English in consultation with acupuncturists both in China and U.S. to treat musculoskeletal pain. The protocol has been piloted in our prior research to demonstrate adequate safety and efficacy in pain reduction.

The delivery of EA will be administered in the following steps:

- 1. History/tongue diagnosis/pulse diagnosis
- 2. Assist patient to lie comfortably on a table
- 3. Identify one focal body area that the patient considers to be the most painful (i.e. knee, ankle, low back). This area will be the primary focus during the entire treatment course.
- 4. Choose at least four acupuncture points from Table 1 to address the pain in the most severe joint/area. The acupuncturist may choose additional acupuncture points or a trigger (ashi/tender point) that may not be located on the meridian, however, please specify on the case report form.
- 5. Identify constitutional complaints of the patient (e.g., general aching, anxiety, depression, fatigue, or poor sleep)
- 6. Choose at least four acupuncture points using the table below, or your own clinical judgment to address the patient's general constitutional symptoms. Please specify points used on the case report form.
- 7. Limit the total number of points to 10-20.
- 8. Clean the skin at needle insertion sites following aseptic technique
- 9. Insert needle to appropriate depth with brief stimulation to achieve "De Qi" sensation
- 10. Connect the four local needling points to a TENS unit at 2 Hz frequency stimulation. Increase electrical stimulation intensity to appropriate level. The patient should feel the stimulation but it should not be painful.
- 11. Set timer for 30 minutes
- 12. Document acupuncture procedure
- 13. Check patient in 15 minutes for comfort
- 14. Turn off electrical stimulation and remove leads. Remove needles and wipe any blood with a sterile cotton-tipped applicator
- 15. Assist patient to slowly get up from the examination table
- 16. Complete documentation of the case report form

Memorial Sloan Kettering Cancer Center IRB Number: 16-1579 A(14) Approval date: 21-Jan-2020

Table 1: Electro-Acupuncture	Point	Selection	Guide
-------------------------------------	-------	-----------	-------

Joint Pain Location	Acupuncture Points					
Shoulder	Jianyu	Jianliao	Jianzhen	Naoshu	Houxi	
	(L.I.15)	(S.J.14)	(S.I.9)	(S.I.10)	(S.I 3)	
Scapula	Tianzong	Bingfeng	Jianwaishu	Gaohuangshu		
_	(S.I.11)	(S.I.12)	(S.I.14)	(U.B.43)		
Elbow	Quchi	Chize	Tianjing	Waiguan	Hegu	
	(L.I.11)	(Lu. 5)	(S.J.10)	(S.J.5)	(L.I.4)	
Hand / Finger	Houxi	Sanjian	Baxie	Hegu		
_	(S.I.3)	(L.I.3)	(Extra)	(L.I.4)		
Нір	Huantiao	Yinmen	Juliao	Quixu		
	(G.B.30)	(U.B.37)	(G.B.29)	(G.B.40)		
Knee	Lianqiu	Dubi	Xiyan	Yanlingquan	Xiangguan	Yinlingquan
	(St.34)	(St. 35)	(Extra)	(G.B.34)	(G.B. 35)	(Sp. 9)
Leg	Chengshan	Feiyang				
	(U.B. 57)	(U.B. 58)				
Ankle	Jiexi	Shangqui	Quixu	Kunlun	Taixi	
	(St.41)	(Sp. 5)	(G.B.40)	(U.B.60)	(K.3)	
Foot / Toe	Gongsun	Shugu	Bafeng	Taixi		
	(Sp.4)	(U.B.65)	(Extra)	(Liv. 3)		
Low Back Pain	Shenshu	Dachangshu	Weizhong	Chengshan	Huatuo	Kunlun
	(U.B 23)	(U.B.25)	(U.B. 40)	(U.B. 57)	(Extra)	(U.B. 60)
Neck Pain	Jianjing	Huatuo	Luozhen	Dazhui	Fengchi	
	(G.B.21)	(Extra)	(Extra)	(GV14)	(G.B. 20)	
General Symptoms						
General Aching	Houxi	Shenmai	Dabao	Geshu	Yinlingquan	Hegu/Taixi
	(S.I. 3)	(U.B. 62)	(Sp.21)	(U.B.17)	(Sp. 9)	(L.I.4/Liv3)
Generalized Anxiety	Neiguan	Taixi	Yin Tang			
	(P.C. 6)	(Liv. 3)	(Extra)			
Generalized Fatigue	Sanxinjiao	Zusanli	Qihai			
	(Sp. 6)	(St.36)	(CV6)			
Sleep	Shenmen	Anmian				
	(Ht.7)	(Extra)				
Depression	Baihui	Ganshu	Taixi			
	(Du.20)	(U.B.18)	(Liv. 3)			

ii. <u>Battle Field Acupuncture (BFA) Procedure</u>: The BFA procedure involves placing tiny (2.5 mm) ASP auricular acupuncture needles into ten well-defined and studied auricular acupuncture points (five points in each ear – See Figure 1). The delivery of BFA is simple and not dependent on specific pain location or diagnoses. The auricular needles are stainless steel, semi-permanent needles, and are designed to stay in the ear for 3-4 days. They fall out naturally as the ear re-epithelizes the site. Since the needles are tiny and the ear is not adjacent to any vulnerable structures, the technique is extremely safe with no significant complications ever reported. ASP needles should be removed after 4 days. Patients are instructed to remove needles before undergoing an MRI



The delivery of BFA will be administered in the following steps:

- 1. The practitioner will direct the patient to sit and ensure that he or she is comfortable, with his or her back well supported.
- 2. The practitioner will clean the right ear using an alcohol pad.
- 3. The practitioner will place the needle in the Cingulate Gyrus point on the clean right ear, making sure to position and insert the needle with the proper technique.
- 4. The practitioner will assist the patient in rising, and guide them in walking for one minute.
- 5. Should the patient feel light-headed, the practitioner will assist them in sitting down.
- 6. Once one minute has transpired, the practitioner will assess the patient's pain level, taking note of the reported pain level.
- 7. If the pain is greater than 0-1, and the patient is willing, practitioner will continue, repeating steps 2-4 on the left ear for the Cingulate Gyrus point.
- 8. If pain has decreased below 1, patient requests the practitioner stop due to discomfort, or the practitioner observes significant vaso-vagal reaction, practitioner will stop inserting needles.
- 9. If patient continues to report pain greater than 0-1 and is willing, practitioner will continue inserting needles following steps 3-4, first in the right ear, then in the left ear at the Thalamus point, the Omega 2 point, Point Zero, and Shen Men point.

Memorial Sloan Kettering Cancer Center IRB Number: 16-1579 A(14) Approval date: 21-Jan-2020

10. The practitioner will once again assess the patient's pain level, ensure they are feeling well, and release the patient.

		<u>Usual Care</u>		<u>Auricular</u> <u>Acupuncture</u>		Electr	<u>oacupuncture</u>
Outcome Measure	Week	n Mean (SD)		n	Mean (SD)	n	Mean (SD)
BPI Pain Severity	0	71	5.6 (1.5)	141	5.0 (1.7)	145	5.2 (1.8)
	12	66	5.0 (2.0)	135	3.1 (2.1)	133	2.7 (2.0)
	24			126	3.0 (2.1)	134	3.0 (2.2)
BPI Pain Interference	0	71	5.3 (2.2)	141	4.7 (2.2)	145	5.1 (2.4)
	12	66	4.4 (2.4)	133	2.3 (2.0)	133	2.2 (2.1)
	24			125	2.2 (2.1)	133	2.5 (2.5)
BPI Worst Pain Item	0	71	7.1 (1.8)	141	6.6 (1.8)	145	6.9 (1.7)
	12	66	6.1 (2.1)	135	4.4 (2.5)	133	3.9 (2.5)
	24			126	4.0 (2.5)	134	4.0 (2.7)
BPI Average Pain Item	0	71	6.1 (1.6)	141	5.4 (1.7)	145	5.6 (1.7)
	12	66	5.4 (1.9)	135	3.2 (2.1)	133	2.9 (2.1)
	24			126	3.2 (2.0)	134	3.1 (2.2)
Pain Medication QAQ Score	0	69	1.7 (2.2)	136	1.6 (2.2)	142	1.6 (2.1)
	12	68	1.7 (2.8)	125	1.1 (1.7)	133	1.1 (1.8)
	24			122	1.1 (1.6)	128	1.1 (1.8)

eTable 1: Descriptive Statistics of Pain Outcome Measures, by Week and Arm

eTable 2. Primary and Seco	ndary	Outcomes (extended	version of manuscri	ipt Table 2) ^a						
		Usual Ca	are (UC)	Electroacupuncture (EA)			Auricular Acupuncture (AA)			
0.1			Change from Baseline,		Change from Baseline,	Difference from UC in Change from Baseline,	Marca (059/ Cl)	Change from Baseline,	Difference from UC in Change from Baseline, Moon (05% Cl)	Difference in Change From Baseline, AA - EA,
Outcome	week	wean (95% CI)	Wealt (95% CI)	Iviean (95% CI)	Wealt (55% CI)	wiedii (35% Ci)	Wean (95% CI)	Wealt (55% CI)	wiedii (95% Ci)	wiedii (55% Ci)
Primary Outcome:	-									
ber Pain Seventy	U	5.23 (5.03, 5.43)		5.25 (5.05, 5.43)			5.23 (5.03, 5.43)			
	12	4.75 (4.37, 5.14)	-0.48 (-0.85, -0.10)	2.84 (2.55, 3.13)	-2.39 (-2.66, -2.12)	-1.92 (-2.43, -1.40)*	3.20 (2.91, 3.49)	-2.03 (-2.30, -1.76)	-1.56 (-2.07, -1.04)*	0.36 (∞, 0.665)°
	24			3.04 (2.76, 3.33)	-2.19 (-2.46, -1.92)		3.24 (2.95, 3.53)	-1.99 (-2.27, -1.72)		0.20 (∞, 0.51) ^d
Secondary Outcomes: ^e										
BPI Pain Interference	0	4.96 (4.74, 5.19)		4.96 (4.74, 5.19)			4.96 (4.74, 5.19)			
	12	4.10 (3.67, 4.53)	-0.86 (-1.28, -0.45)	2.20 (1.88, 2.52)	-2.76 (-3.06, -2.46)	-1.90 (-2.40, -1.40)	2.44 (2.12, 2.76)	-2.52 (-2.82, -2.22)	-1.66 (-2.16, -1.16)	0.24 (-0.17, 0.64)
	24			2.49 (2.17, 2.81)	-2.47 (-2.77, -2.17)		2.49 (2.17, 2.82)	-2.47 (-2.78, -2.16)		0.00 (0.41, -0.41)
BPI Worst Pain	0	6.85 (6.61, 7.09)		6.85 (6.61, 7.09)			6.85 (6.61, 7.09)			
	12	5.90 (5.40, 6.40)	-0.95 (-1.45, -0.45)	3.90 (3.54, 4.27)	-2.94 (-3.31, -2.58)	-2.00 (-2.59, -1.40)	4.48 (4.12, 4.84)	-2.37 (-2.73, -2.00)	-1.42 (-2.01, -0.82)	0.58 (0.09, 1.06)
	24			4.00 (3.64, 4.36)	-2.85 (-3.21, -2.49)		4.26 (3.89, 4.63)	-2.58 (-2.96, -2.21)		0.27 (-0.22, 0.76)
BPI Average Pain	0	5.60 (5.40, 5.80)		5.60 (5.40, 5.80)			5.60 (5.40, 5.80)			
_	12	5.14 (4.75, 5.53)	-0.46 (-0.84, -0.07)	3.07 (2.78, 3.35)	-2.53 (-2.81, -2.25)	-2.07 (-2.53, -1.61)	3.32 (3.03, 3.61)	-2.28 (-2.55, -2.00)	-1.82 (-2.28, -1.36)	0.25 (-0.12, 0.63)
	24			3.22 (2.93, 3.51)	-2.38 (-2.65, -2.10)		3.42 (3.13, 3.72)	-2.17 (-2.46, -1.89)		0.20 (-0.17, 0.58)
PROMIS Physical Health	0	40.68 (39.93, 41.42)		40.68 (39.93, 41.42)			40.68 (39.93, 41.42)			
	12	41.09 (39.80, 42.37)	0.41 (-0.76, 1.58)	44.99 (44.01, 45.98)	4.32 (3.48, 5.15)	3.91 (2.49, 5.32)	45.17 (44.17, 46.17)	4.50 (3.64, 5.35)	4.09 (2.66, 5.51)	0.18 (-0.98, 1.34)
	24			44.28 (43.29, 45.26)	3.60 (2.77, 4.43)		45.28 (44.26, 46.30)	4.60 (3.73, 5.48)		1.00 (-0.18, 2.18)
PROMIS Mental Health	0	45 75 (44 82 46 69)		45 75 (44 82 46 69)			45 75 (44 82 46 69)			
	12	45.02 (43.53, 46.52)	-0.73 (-2.04, 0.58)	47.60 (46.42, 48.78)	1.85 (0.92, 2,78)	2,58 (0.99, 4,16)	48.47 (47.27, 49.66)	2.71 (1.76, 3.67)	3.44 (1.84, 5.04)	0.87 (-0.44, 2.17)
	24			47.20 (46.02, 48.38)	1.45 (0.52, 2.38)		48.67 (47.46, 49.88)	2.92 (1.94, 3.89)		1.47 (0.15, 2.79)
Pain Medication QAQ Scc	0	1.58 (1.38, 1.78)		1.58 (1.38, 1.78)			1.58 (1.38, 1.78)			
	12	1.71 (1.37, 2.04)	0.13 (-0.17, 0.43)	1.14 (0.88, 1.40)	-0.44 (-0.66, -0.23)	-0.57 (-0.94, -0.21)	1.19 (0.92, 1.46)	-0.39 (-0.61, -0.17)	-0.52 (-0.88, -0.15)	0.05 (-0.25, 0.35)
	24			1.15 (0.88, 1.41)	-0.43 (-0.65, -0.21)		1.30 (1.03, 1.57)	-0.28 (-0.50, -0.06)		0.15 (- 0.15, 0.46)

a. For each outcome, estimates are derived from a linear mixed model with baseline means constrained to be equal across study arms. The dependent variable vector included the pre-randomization baseline (week 0) assessment, as well as all post-randomization assessments at weeks 4, 10, 12, 16, and 24. The independent variables were the randomization stratification variables (accrual site and baseline opioid use), treatment arm, week (categorical), and the arm-by-week interaction. A patient-level random intercept was included in the model to account for the repeated outcome measurements within patients.

b. Primary endpoint. Point estimates with 97.5% confidence intervals (adjusted for 2 comparisons) are presented. P<0.001 for both comparisons of treatment arms with UC for differences in BPI Pain Severity change from baseline to week 12.

c. Primary endpoint comparison of non-inferiority of AA to EA at Week 12. Point estimate with one-sided 95% confidence interval is presented. The non-inferiority margin was 0.657. The one-sided 95% confidence interval contains the non-inferiority margin; therefore, we cannot conclude that AA is non-inferior to EA at our prespecified p < 0.05 threshold. The p-value for the non-inferiority test was p = 0.055.

d. Secondary endpoint comparison of non-inferiority of AA to EA at Week 24. Point estimate with one-sided 95% confidence interval is presented. The non-inferiority margin was 0.657. The one-sided 95% confidence interval did not contain the non-inferiority margin, supporting the non-inferiority of AA to EA at Week 24 at the p < 0.05 threshold. The p-value for the non-inferiority test was p = 0.007. This test was not prespecified as part of our primary endpoint comparisons and was conducted post-hoc as an exploratory analysis.

e. Secondary outcomes were not adjusted for multiple comparisons. Results are presented as point estimates with 95% confidence intervals.

Abbreviations: CI, confidence interval; BPI, Brief Pain Inventory; PROMIS, Patient-Reported Outcomes Measurement Information System; QAQ, Quantitative Analgesic Questionnaire.